Stability indicating methods for the determination of clozapine

Application of nickel-doped graphene nanotubes to modified GCE as a sensitive electrochemical sensor for the antipsychotic drug clozapine in spiked human blood serum samples

Clozapine (CLZ) is one of the most vital medications for managing schizophrenia, and the timely measurement of CLZ levels has been recognized as an obstacle to the wider use of CLZ. Herein, for the first time, nickel-doped graphene nanotubes (Ni@GRNT) were used to construct an electrochemical CLZ sensor by drop coating Ni@GRNT suspension on a glassy carbon electrode. The Ni@GRNT was synthesized and characterized using X‐ray diffraction, scanning electron microscopy, and energy-dispersive X-ray spectroscopy. The electrochemical behavior and influence of different physicochemical factors of sensing electrodes were investigated by using cyclic voltammetry, EIS technique, and differential pulse voltammetry techniques. Also, the catalytic rate constant (kcat) and the transfer coefficient (α) were calculated. The modified electrode illustrated satisfactory linear range, detection limit (LOD), reusability, and reproducibility results. At optimal experimental conditions, measurements can be performed at a broad linear dynamic range of 0.3 nmol L−1–60.0 μmol L−1 CLZ and with a LOD of 0.1 nmol L−1. The sensitivity value was estimated to be 3.06 μA µmol L−1 cm−2. Ultimately, this platform was successfully used for CLZ sensing in spiked human blood serum and tablet samples with an accuracy of > 93%.

Graphical abstract

Stability of Compounded Clozapine 25 mg/mL and 50 mg/mL Suspensions in Plastic Bottles

BACKGROUND

Clozapine oral suspension is not commercially available in Canada but is required for administration to patients who cannot swallow intact tablets.

OBJECTIVE

To evaluate the stability of 25 mg/mL and 50 mg/mL clozapine suspensions prepared in a 50:50 mixture of methylcellulose gel 1% and Oral Syrup (flavoured syrup vehicle, Medisca Pharmaceutique Inc) and stored in amber glycol-modified polyethylene terephthalate (PET-G) bottles over 120 days at 4°C and 25°C.

METHODS

This study used a validated reverse-phase stability-indicating liquid chromatographic method capable of quantifying clozapine, 3 known degradation compounds, a known impurity, and an unknown compound. Three separate batches of 25 mg/mL and 50 mg/mL clozapine suspensions were prepared, divided into 100-mL aliquots, and stored in 120-mL PET-G bottles. Half of the bottles from each concentration were stored at room temperature (20°C to 25°C) and the other half were stored in the refrigerator (2°C to 8°C). On study days 0, 28, 60, 90, and 120, concentrations of clozapine, each of the 3 known clozapine degradation products, a known impurity, and an unknown compound were determined.

RESULTS

When suspensions were stored in PET-G containers at room temperature or under refrigeration for 120 days, the concentration of clozapine remained above 95% of initial concentration, and the measured concentration of degradation products and impurities did not exceed the 0.5% limits set by regulatory authorities worldwide. The proportion of the initial concentration of clozapine remaining on day 120, based on fastest degradation rate with 95% confidence (1-sided), exceeded 92%, and the only degradation product found (clozapine lactam, 0.2%) and an unknown impurity (0.2%) also did not exceed allowable limits.

CONCLUSIONS

Compounded clozapine suspensions of 25 mg/mL and 50 mg/mL can be stored in amber PET-G containers for up to 120 days after preparation with storage at room temperature or under refrigeration.

A Comprehensive Review on Importance and Quantitation of Atypical Antipsychotic Drugs and their Active Metabolites in Commercial Dosage Forms

Background:

Schizophrenia is a severe mental illness that affects more than twenty-one million people throughout the world. Schizophrenia also causes early death. Schizophrenia and other related psychotic ailments are controlled by the prescription of antipsychotic drugs, which act by blocking certain chemical receptors in the brain and thus relieves the symptoms of psychotic disorder. These drugs are present in the different dosage forms in the market and provided in a certain amount as per the need of the patients.

Objective:

Since such medications treat mental disorders, it is very important to have a perfect and accurate dose so that the risk factor is not affected by a higher or lower dose, which is not sufficient for the treatment. For accurate assay of these kinds of drugs, different analytical methods were developed ranging from older spectrophotometric techniques to latest hyphenated methods.

Results:

The current review highlights the role of different analytical techniques that were employed in the determination and identification of antipsychotic drugs and their metabolites. Techniques such as spectrophotometry, fluorimetry, liquid chromatography, liquid chromatography-mass spectrometry, gas chromatography, and gas chromatography-mass spectrometry employed in the method development of such antipsychotic drugs were reported in the review. Different metabolites, identified using the hyphenated techniques, were also mentioned in the review. The synthesis pathways of few of the metabolites were mentioned.

Conclusion:

The review summarizes the analyses of different antipsychotic drugs and their metabolites. A brief introduction of illnesses and their symptoms and possible medications were highlighted. Synthesis pathways of the associated metabolites were also mentioned.

Characterization of forced degradation products of clozapine by LC-DAD/ESI-Q-TOF

Forced degradation of clozapine in solutions under acidic, basic, neutral, photo UV-vis, photo UVC and oxidative stress conditions was investigated and structural elucidation of its degradation products was performed with the use of the UHPLC-DAD system coupled with accurate hybrid ESI-Q-TOF mass spectrometer. The developed method allows to collect all essential data for the determination of degradation kinetics and for the structural elucidation of the formed products. Six degradation products were found and their masses and formulas were obtained with high accuracy (0.61-3.75ppm). For all the analyzed compounds MS/MS fragmentation spectra were also obtained allowing structural elucidation of the unknown degradation products. It was found that the decomposition of clozapine yields the first-order kinetic reaction in all stress conditions and it is fragile towards acidic hydrolysis and oxidative conditions. Additionally, PCA analysis of registered TOF (MS) forced degradation profiles of clozapine shows no differences between the samples obtained from pharmaceutical formulation and bulk substance.

Formulation and characterization of clozapine and risperidone co-entrapped spray-dried PLGA nanoparticles

In the current study, polylactide-co-glycolide (PLGA) nanoparticles entrapping both clozapine (CLZ) and risperidone (RIS) were formulated by spray-drying using Buchi Nano Spray Dryer B-90 (Flawil, Switzerland). Parameters such as inlet temperature, spray mesh diameter, sample flow rate, spray rate and applied pressure were optimized to produce nanoparticles having desired release profile using both low- and high-molecular weight PLGA polymer. Smallest size nanoparticle of size around 248 nm could be prepared using a 4.0 μm mesh diameter with low-molecular weight polymer. The load of CLZ and RIS was 126.3 and 58.2 μg/mg of polymer particles, respectively. Entrapment efficiency of drugs in PLGA nanoparticles was 94.74% for CLZ and 93.12% for RIS. Both the drugs released continuously from the nanoparticle formulations. PLGA nanoparticles formulated using low-molecular weight polymer released around 80% of the entrapped drug over 10 days of time. Nature of drug inside polymer particles was amorphous, and there was no chemical interaction of CLZ and RIS with polymer. Polymeric nanoparticles were found to be non-toxic in nature using PC12 cell line. This nanospray drying process proved to be suitable for developing polymeric nanoformulation delivering dual drugs for the treatment of Schizophrenia.

Development of a method of clozapine dosage by selective electrode to the iodides

Clozapine (Leponex(®)), the main neuroleptic indicated in the treatment of resistant schizophrenia, requires therapeutic monitoring because of its side effects and the individual variability in metabolism. In addition, several cases of intoxication by this drug were described in the literature. In this work, we studied the indirect dosage of clozapine by selective electrode to the iodides for the optimization of an analytical protocol allowing therapeutic monitoring and the diagnosis of intoxication and/or overdose. Our results showed that the developed method is linear between 0.05 and 12.5 µg/mL (r = 0.980), with a limit of detection of 0.645.10(-3) µg/mL. It presents good precision (coefficient of variation less than 4%) and accuracy (coefficient less than 10%) for all the studied concentrations. With a domain of linearity covering a wide margin of concentrations, this method can be applicable to the dosage of clozapine in tablets and in different biological matrices, such as plasma, urines, and postmortem samples.

An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients

While clozapine is the acknowledged superior pharmacotherapeutic for the treatment of schizophrenia, the side effect profile, which includes potentially fatal complications, limits its usefulness. Central administration of clozapine directly into the brain could circumvent many of the side effect issues due to the dramatic reduction in dose and the limitation of the drug primarily to the CNS. The present study demonstrates that clozapine can be formulated as a stable solution at physiological pH, which does not have in vitro neurotoxic effects at concentrations which may be effective at treating symptoms. Acute central administration improved auditory gating deficits in a mouse model of schizophrenia-like deficits. Assessment of behavioral alterations in rats receiving chronic central infusions of clozapine via osmotic minipump was performed with the open field and elevated plus mazes. Neither paradigm revealed any detrimental effects of the infusion. While these data represent only an initial investigation, they none-the-less suggest that central administration of clozapine may be a viable alternate therapeutic approach for schizophrenia patients which may be effective in symptom reduction without causing behavioral or neurotoxic effects.

Electrochemical Behavior and Determination of Clozapine on a Glassy Carbon Electrode Modified by Electrochemical Oxidation

The adsorptive and electrochemical behaviors of clozapine (CLZ) were investigated on a glassy carbon electrode that was electrochemically treated by anodic oxidation at +1.8 V, following potential cycling in the potential range from -0.8 to 1.0 V vs. Ag/AgCl reference electrode. Based on the obtained electrochemical results, an electrochemical-chemical (EC) mechanism was proposed to explain the electrochemical oxidation of CLZ. The resulting electrochemically pretreated glassy carbon electrode (EPGCE) showed good activity to improve the electrochemical response of the drug. CLZ was accumulated in a phosphate buffer (pH 6) at a certain time, and then determined by differential pulse voltammetry. The anodic and cathodic peak currents showed a linear function in the concentration ranges of 0.1 - 1, 1 - 10 and 10 - 100 microM with various accumulation times. The proposed method was successfully used for the determination of CLZ in pharmaceutical preparations. The preconcentration medium-exchange approach was utilized for the selective determination of the drug in spiked urine samples with satisfactory results. The recovery levels of the method reached 96% (RSD, 1.8%) and 90% (RSD, 2.8%) for urine and plasma samples, respectively.

Spectrophotometric determination of clozapine based on its oxidation with bromate in a micellar medium

A simple and sensitive spectrophotometric method was developed for the determination of clozapine in its dosage forms. The method is based on the reaction of the drug with potassium bromate in a perchloric acid medium to produce an intense yellow colored species exhibiting a maximum absorption at 308 nm. Beer's law is obeyed for up to 12.0 microg ml(-1) with a correlation coefficient (n = 6) of 0.9998 and a detection limit (3S(b)) of 0.1 microg ml(-1). The molar absorptivity is 1.986 x 10(4) l mol(-1) cm(-1). The various experimental parameters affecting the development and stability of the colored oxidation product were carefully studied and optimized. The proposed method was successfully applied to the determination of clozapine in its dosage forms. The results obtained were in good agreement with those obtained using the B.P. official method.

Adsorptive stripping voltammetric quantification of the antipsychotic drug clozapine in bulk form, pharmaceutical formulation and human serum at a mercury electrode

Using the cyclic voltammetry technique and the Britton-Robinson buffer (pH 2-10) as a supporting electrolyte, clozapine was found to reduce at the hanging mercury drop electrode in a single two-electron irreversible step corresponding to reduction of the azomethine group of the seven-member heterocyclic ring. Based on the interfacial adsorptive character of clozapine onto the hanging mercury drop electrode, a validated square-wave adsorptive cathodic stripping (SWAdCS) voltammetric procedure was described for the quantification of bulk clozapine with limits of detection and quantitation of 4.5 x 10(-10) and 1.5 x 10(-9) M, respectively. The proposed procedure was successfully applied to the quantification of the drug in pharmaceutical formulation (Leponex) and human serum without the necessity for samples' pretreatment or any time-consuming extraction or evaporation steps prior to the analysis. The limits of detection and quantitation of clozapine in spiked human serum were found to be 1 x 10(-9) and 3.3 x 10(-9) M, respectively. The proposed procedure for quantification of clozapine in bulk form, tablets and human serum has the advantage of being simple, rapid, sensitive, precise and inexpensive compared to most of the reported methods.

Optimization and validation of a capillary zone electrophoretic method for the simultaneous analysis of four atypical antipsychotics

A capillary zone electrophoretic method has been developed and optimized for separation of four atypical antipsychotics (AAPs): clothiapine (cT), clozapine (cZ), olanzapine (O), and quetiapine (Q). A three-level full-factorial design was applied to study the effect of the pH and molarity of the running buffer on separation. Combination of the studied parameters permitted the separation of the four AAPs, which was best carried out using 80 mM sodium phosphate buffer (pH 3.5). The same system can also be applied for the quantitative determination of these compounds. The method was then validated regarding linearity, precision, and accuracy. Especially, the possibility of simultaneous quantification and identification of the active ingredient in the finished product is very attractive.